AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
AMGEN INC balance sheet
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 69.5%
- Operating margin
- 30.0%
- Net margin
- 23.0%
- Return on equity, FY2025
- 106.1%
Financial strength
- Current ratio
- 1.37
- Debt to equity
- 4.90
- Debt to assets
- 59.9%
- Cash to current liabilities
- 54.9%
Valuation
- P/E ratio
- 26.4
- Price to sales
- 6.07
- Price to book
- 19.78
- Dividend yield
- 2.27%